Galmed 1-Year Results Of The Open-Label Part Of Its Global Phase 3 Trial Of Aramchol In 150 Patients With NASH And Fibrosis Have Been Published In Hepatology
Galmed 1-Year Results Of The Open-Label Part Of Its Global Phase 3 Trial Of Aramchol In 150 Patients With NASH And Fibrosis Have Been Published In Hepatology
Galmed发布了在150名NASH和纤维化患者中进行的全球第3期Aramchol研究的开放标签部分的1年结果，已在《肝病学》杂志上发表。
- The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)
- Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis
- Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology
- 该论文重新强调了Aramchol 300mg BID在代谢性功能障碍相关脂肪肝炎（MASH）患者中的显著抗纤维化作用
- 数据已经通过3个客观测量指标进行确认：NASH CRN、成对排序阅读和人工智能（AI）定量数字分析
- 数字病理图像分析（DIA）在抗纤维化试验中生成了连续的组织学纤维化评分，比传统病理学具有更高的灵敏度和更大的动态范围，量化了抗纤维化效果
TEL AVIV, Israel, Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced today that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in Hepatology.
以色列特拉维夫，2024年9月25日 / PRNewswire / - 纽交所：GLMD）（“Galmed”或“公司”）， Galmed Pharmaceuticals Ltd是一家临床阶段的生物制药公司，致力于肝脏、代谢和纤维炎症疾病宣布，其全球III期Aramchol试验（ARMOR）150名NASH患者和纤维化（ARCON）的开放标签部分的1年结果已经在肝病学杂志上发表
资讯热榜
更新时间